Certara 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Third-quarter 2026 revenue from continuing operations was $94.9 million, up 4% year over year, and total bookings were $92.5 million, up 4%.
- Software revenue grew 11% to $48.8 million, while software bookings were $46.9 million, up 15%; trailing 12-month software bookings were $202.4 million, up 8%.
- Services revenue was $46.1 million, down 2% year over year but up 3.5% sequentially; trailing 12-month services bookings were $206.6 million, down 2%, with a trailing 12-month book-to-bill of 1.15.
- Adjusted EBITDA increased 6% to $30.2 million, and adjusted EBITDA margin was 31.8%, compared with 31.5% in the prior-year period and 28.1% in the 2nd quarter.
- The net loss from continuing operations was $3.6 million, compared with $4.8 million in the prior-year period; adjusted net income was $13.5 million, and adjusted diluted earnings per share were $0.09.
- Certara ended the quarter with $214.9 million in cash and cash equivalents, approximately $293 million outstanding on its term loan, and $100 million available under its revolving credit facility.
- Certara completed the divestiture of its regulatory medical writing business on May 8th; results from that business are reported in discontinued operations.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Certara third quarter 2026 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Jay Liu, Investor Relations at LifeSci Advisors.
Please go ahead. Good morning, everyone.
Thank you all for participating in today's conference call. On the call from Certara, we have Jon Resnick, Chief Executive Officer, and Faiz Mohammed, Interim Chief Financial Officer. Earlier today, Certara released financial results for the quarter ending September 30, 2026. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements, and actual results may differ materially from those expressed or implied in the forward-looking statements. Please refer to slide two in the accompanying presentation titled "Third Quarter 2026 Financial Results" for additional information, which you can find on the company's investor relations website. In the remarks or responses to questions, management may mention some non-GAAP financial measures.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP measures are available in the recent earnings press release available on the company's website. Please refer to the reconciliation tables in the accompanying materials for additional information. This conference call contains time-sensitive information and is accurate only as of today, November 5, 2026. Certara disclaims any obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. With that, I will turn the call over to Jon.
Thank you, Jay. Thank you all for joining today. When I hosted my first earnings call in February, I shared with you my initial impressions of Certara, that we have an extraordinary business, one that is strategically critical to the future of drug development. On that February call, I also shared that 2026 would be about improving the ways we operate, reinvigorating growth, and setting the business up to realize its full potential. What followed was attention to a focused strategy and targeted portfolio businesses, placing customers at the center of everything we do, and a dedication to execution and operations. Over the past three quarters, we have completed the divestiture of the Regulatory and Medical Writing business, reorganized our business around how customers buy our software and services, and brought in key talent to strengthen our commercial and product leadership teams.
We have also moved quickly to embed AI across our offerings and our operations, and to define a multi-pronged strategy to accelerate growth. There is more work to do, but we are executing against that plan. Turning to Q3, I am pleased to say the business is showing signs of strengthening. Revenue for the quarter was $94.9 million, up 4% year-over-year on a continuing operations basis. Adjusted EBITDA was $30.2 million, up 6% from the prior year, with a 31.8% margin, consistent with the operational actions that we have started to implement. Today, we announced the appointment of Grant Peterson as Chief Product Officer. Grant previously served as CPO at Conga, and before that, was CTO at DocuSign. Grant's mandate is to focus our portfolio investments on accelerating growth in both existing and new products, guided by customer input and the broader technology ecosystem. Turning to software. In Q3, software revenue grew 11% to $48.8 million, our first double-digit organic software growth quarter in two years.
Software bookings were $46.9 million, up 15% year-over-year. Software now represents more than half of our revenue. Notably, we are seeing growth across all of our core products, with momentum and opportunity for continued expansion. For Phoenix Cloud, we have now moved nearly 10% of all accounts to the cloud. We expect future growth to be fueled by additional cloud conversion of our strong pipeline and adoption of our new AI offerings. For Pinnacle 21, we recently expanded a multi-million dollar relationship with a strategic partner. This is a good example of the adoption path for advanced tier modules of P21, MDR, Data Exchange, and CRF Creator.
For Simcyp, we continue to see a high level of engagement from our customers and the scientific community, as well as historically strong renewal rates. Our annual Simcyp Consortium meeting brought together our major customers in London to share insights, advanced modeling techniques, and shape the future of Simcyp software. We have previously shared the product and operational benefits powered by AI. We are also leveraging our AI expertise in drug development to deliver an integrated AI platform that works across the drug development cycle. We believe our AI platform approach and direction will have the potential to fundamentally change how our clients can adopt the breadth of Certara solutions. Our early AI focus is to deliver our products as an agentic component that can be integrated into customer workflows. Our AI path includes an MCP-enabled data integration platform that allows customers to access Certara software and proprietary data.
We will continue to expand how we use AI to accelerate and broaden the delivery of our scientific content and applications. In 2027, we expect these new capabilities to further contribute to the growth and positioning of Certara. These transformations have the potential to drive increased adoption, integration, and sales of our existing technology in three ways: by deepening software value to our customers and the connected development cycle, by creating new opportunities to engage with executive-level decision-makers, and ultimately, by introducing software plus services as integrated solutions to accelerate better decisions, whether dosing, trial design, or go/no-go determinations. Now, moving to services. Service revenue was $46.1 million, down 2% year-over-year. Service bookings were $45.6 million in the quarter, with a trailing 12-month services book-to-bill of 1.15.
Over the past two quarters, we have divested non-core offerings, aligned software and services to take advantage of the flywheel, rebalanced our engagement model back towards specialists, and greatly expanded our customer outreach. The potential impact of these steps will take time to show in our numbers. Still, we have seen some incremental improvement. Services revenue grew sequentially in Q3 by 3.5%. Certara's scientific talent runs deep, with over 400 scientists holding advanced degrees, many of whom are recognized leaders in their fields with extensive peer-reviewed publications. Our experts play a critical role in shaping innovation and making biosimulation accessible to our customers in drug discovery and development. Our leadership position is evidenced by the work we do for our customers. Most recently, we supported a top 10 European pharmaceutical client with a model-based meta-analysis applied to obesity treatment trials.
This novel quantitative approach allowed the client to optimally position the phase III asset in a crowded field across different mechanisms and endpoints. We worked with a U.S.-based biotechnology company to predict the first-in-human starting dose for its in vivo CAR T candidate using our QSP CAR T model, optimizing safety and efficacy for the asset. We partnered with a U.S.-based company that is licensing a novel compound from China. We are building models that connect early and late-phase studies to enable a phase III FDA submission using Chinese and U.S. data, aimed at reducing redundant studies and accelerating the U.S. filing path. Finally, we are supporting a U.S. biotechnology company that is advancing assets other developers set aside for rare pediatric cancers. Our teams use modeling and simulation to bridge existing clinical and non-clinical data to pediatric populations, allowing sponsors to make critical path decisions with more precision.
At Certara, we are strongest when we bring together all of our assets. In Q3, one of our major partners benefited from this approach, which contributed to their achieving a major milestone. In this example, a biotech partner developing a novel oncology agent received approval under priority review for a cancer with historically few treatment options. This partnership spanned four years and more than two dozen Certara software and service solutions. We began working with this team pre-IND and supported their clinical pharmacology organization all the way through a successful NDA, including drug interaction modeling, phase I and phase II PK analysis, and cardiac safety strategy. This exemplifies what differentiates Certara. When our software, science, and regulatory expertise are integrated across the development path, partners get continuity and confidence, and we become embedded in how they make decisions.
We see significant opportunities to replicate this model in the wider customer base, and we are organizing our strategies and our resources behind this approach. To capture opportunities like this, we are reimagining Certara's commercial organization. Our new CCO is moving quickly to transform our customer engagement. This transformation isn't just about selling with greater intensity. It's also about changing who we sell to and how we sell to them, leading with our science and innovation as we bring the full suite of our capabilities to our customers. We are putting greater sales and marketing resources against segments like biotech, mid-sized pharma, CROs, and expanding our commercial footprint globally. To better reach mid-sized and biotech customers, we have developed outreach that leverages refined criteria, such as therapeutic areas or modalities, where our proven case studies are directly and immediately applicable.
For example, our success using modeling to support regulatory filings for GLP-1 therapies has resulted in increased outreach to other customers working in that therapeutic area. We are engaging emerging biotech early, before they scale. In September, our Boston Biotech Forum drew 90 attendees from more than 70 companies. This programming is part of a larger campaign to deepen our relationships in this important sector. APAC is relatively small for us today, but we see outsized growth potential. With this in mind, we have begun expanding in Asia with roadshows in China, Japan, and Korea. This approach has quickly brought us into contact with essential stakeholders in the region, notably including a delegation from the Korean government. We have also accelerated several operational improvements, including pricing reviews, incentives alignment, integrating our scientific experts into the sales process, a dedicated customer service function, and enhanced product training.
We have a distinguished history of sustained global regulatory relationships. We also continue to be at the forefront of certain important advances adopted by regulators. This quarter, the FDA competitively awarded Certara contracts at CDER for its DataFit program and CBER for its CASA-CV clinical data validation programs. The FDA has relied on Pinnacle 21 since 2011, and these awards extend that relationship at both centers. The FDA also engaged our Simcyp team on a three-year research contract to advance biosimulation of dermal products. Certara is helping new approach methodologies, or NAMs, move from concept to routine use. Our scientists work with global regulators and industry consortia to define what credible NAM evidence looks like. We advance our modeling technologies and work with customers on early use cases that test where these approaches can support regulatory decisions now and in the future.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
